Boston Scientific has claimed a new approval from the FDA for its Farapulse pulsed field ablation system, expanding its use ...

Boston Scientific’s Farapulse Pulsed Field Ablation System is now approved for treating persistent atrial fibrillation, ...

Boston Scientific Corporation (NYSE: BSX) has received U.S. Food and Drug Administration (FDA) approval to expand the ...

Boston Scientific (NYSE: BSX) announced that the FDA approved an expansion to the label of its Farapulse pulsed field ...

Boston Scientific receives US FDA approval for expanded labelling of Farapulse PFA System: Marlborough, Massachusetts Tuesday, July 8, 2025, 11:00 Hrs [IST] Boston Scientific Corp ...

Boston Scientific (NYSE:BSX) recently achieved FDA approval to expand the FARAPULSE™ Pulsed Field Ablation (PFA) System's use, enhancing treatment options for persistent atrial fibrillation. This ...

Boston Scientific Corp. gained a second U.S. FDA approval for its Farapulse pulsed field ablation catheter, expanding its use into drug-refractory, symptomatic persistent atrial fibrillation (AF) in ...

Boston Scientific reported that electrophysiology sales grew 172% in Q4 2024, driven by an uptake of its Farapulse pulsed ...

- FARAPULSE becomes first company in the world to commercialize a cardiac PFA system - MENLO PARK, Calif., Jan. 29, 2021 /PRNewswire/ - FARAPULSE Inc. ("FARAPULSE" or "the Company") today ...

Boston Scientific Corporation (NYSE: BSX) has received U.S. Food and Drug Administration (FDA) approval to expand the instructions for use (IFU) labeling for the FARAPULSE™ Pulsed Field Ablation (PFA) ...

“The Farapulse is non-thermal. It doesn’t heat up or freeze tissue. We deliver electric fields at the tissue, and the way it kills is by opening up pores and cell membranes,” stated Dr. Gibson.